Abstract 3414
Background
Angiosarcoma (AS) is a rare malignancy with a heterogeneous clinical presentation and genetic background. Different clinical AS subtypes can be envisaged, including: visceral, deep-seated soft tissue (ST), radiation induced (RT) and UV associated (UV) origin. To better understand their distinct biology and clinical outcome we investigated DNA methylation profiles, chromosomal stability and survival of these four subtypes.
Methods
After ethical approval, FFPE samples of AS from visceral, ST, RT and UV origin were collected from a nationwide search by the Dutch nationwide network and registry of histo- and cytopathology. DNA was extracted for methylation profiling with the Illumina Infinium MethylationEPIC array (German Cancer Research Center, Heidelberg, Germany). Quality control and unsupervised hierarchical clustering based on the 1% most varying methylation probes took place at Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Copy number profiles were generated for chromosomal stability assessment. Anonymized clinical data were obtained from the Netherlands Cancer Registry.
Results
DNA methylation profiling and unsupervised hierarchical clustering of 36 AS samples (6 visceral, 5 ST, 14 RT, 11 UV), revealed two main clusters (A and B) and four subclusters (Table). The different clusters corresponded with clinical origin, showing enrichment of UV cases in cluster A1 and RT cases in cluster A2. Cluster A showed significantly more chromosomal aberrations and better median overall survival compared to cluster B (22.2 vs 5.5 months, p = 0.046).Table:
1711P Cluster characteristics
Cluster | A1 | A2 | B1 | B2 |
---|---|---|---|---|
Patients | 7 | 11 | 7 | 11 |
Subtype | 7 UV | 10 RT, 1 ST | 4 ST, 3 Visceral | 4 RT, 4 UV, 3 Visceral |
Median survival (months, range) | 22 (2-106) | 23 (1-281) | 4 (2-55) | 7 (0-40) |
Conclusions
In this novel DNA methylation profiling study, we demonstrated for the first time four different AS clusters. These clusters strongly correlated with clinical origin, chromosomal stability and overall survival. Further research is warranted in a larger patient cohort to better define the clinical significance of the different clusters.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
HDKT (Honderdduizend Keer een Tientje).
Disclosure
I.M.E. Desar: Research grant / Funding (institution): Novartis. W.T. van der Graaf: Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
5054 - Inhibition of Rspo-Wnt pathway Facilitates Checkpoint Blockade Therapy by anti-RSPO3 antibody (DBPR117)
Presenter: John Hsu
Session: Poster Display session 1
Resources:
Abstract
3305 - A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumors
Presenter: Jürgen Krauss
Session: Poster Display session 1
Resources:
Abstract
5353 - Phase 1/2 Study of 9-ING-41, a small molecule selective Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors
Presenter: Benedito Carneiro
Session: Poster Display session 1
Resources:
Abstract
3946 - Trial in progress: a Phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumors (NCT03447314).
Presenter: Aaron Hansen
Session: Poster Display session 1
Resources:
Abstract
3449 - Radiographic Phenotyping to Identify Intracranial Disseminated Recurrence in Brain metastases Treated With Radiosurgery Using Contrast-enhanced MR Imaging
Presenter: CheYu Hsu
Session: Poster Display session 1
Resources:
Abstract
4553 - Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer
Presenter: Lijuan Chen
Session: Poster Display session 1
Resources:
Abstract
4942 - Response assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: a comparison of RECIST 1.1, RANO and iRANO criteria
Presenter: Emilie Le Rhun
Session: Poster Display session 1
Resources:
Abstract
3529 - Management of multiple brain metastases by Staged SRS focusing on utmost risk lesions
Presenter: shaoqun Li
Session: Poster Display session 1
Resources:
Abstract
5315 - Whole brain radiotherapy plus simultaneous in-field boost versus whole brain radiotherapy plus fractionated stereotactic radiotherapy for multiple brain metastases of non-small cell lung cancer
Presenter: Lu Li
Session: Poster Display session 1
Resources:
Abstract
1116 - 3D based texture analysis serving as potential diagnostic factor in discriminating primary central nervous system lymphoma from metastatic brain tumors: A preliminary study
Presenter: Wen Guo
Session: Poster Display session 1
Resources:
Abstract